Radiopharmaceuticals Market to reach USD 16.6 billion by 2032 and grow at a CAGR of 10.4%.
All nuclear medicine sectors have experienced tremendous growth in the radiopharmaceutical industry. This is due to its crucial use in diagnosis and treatment for many conditions. Radiopharmaceuticals are drugs that enable clear visualization of the body\'s internal functions and aid in the early detection and therapy of diseases such as cancer, cardiovascular diseases, or neurological disorders. Neurological disorders lead the rankings for the cause of disability-adjusted life years, and a 2020 study in The Lancet identifies them as the second leading cause of death in the world, contributing to about 9 million deaths annually. However, for such conditions affecting millions around the globe, services and support are abysmally low, especially in low- and middle-income countries.